177 related articles for article (PubMed ID: 19626462)
1. Health utility scores of colorectal cancer based on societal preference in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Qual Life Res; 2009 Oct; 18(8):1095-103. PubMed ID: 19626462
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
[TBL] [Abstract][Full Text] [Related]
3. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Rittweger K; Gilberg F; Saltz L
Br J Cancer; 2011 Jun; 105(1):58-64. PubMed ID: 21673685
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials.
Shiroiwa T; Fukuda T; Tsutani K
Br J Cancer; 2009 Jul; 101(1):12-8. PubMed ID: 19491895
[TBL] [Abstract][Full Text] [Related]
5. Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
Tse VC; Ng WT; Lee V; Lee AW; Chua DT; Chau J; McGhee SM
BMC Cancer; 2011 Jul; 11():288. PubMed ID: 21740590
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
Wen F; Yao K; Du ZD; He XF; Zhang PF; Tang RL; Li Q
World J Gastroenterol; 2014 Dec; 20(47):17976-84. PubMed ID: 25548497
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].
Lu GC; Fang F; Li DC
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):152-5. PubMed ID: 20403249
[TBL] [Abstract][Full Text] [Related]
9. Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer.
Conroy T; Hebbar M; Bennouna J; Ducreux M; Ychou M; Llédo G; Adenis A; Faroux R; Rebischung C; Kockler L; Douillard JY
Br J Cancer; 2010 Jan; 102(1):59-67. PubMed ID: 19920832
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis.
Chiu J; Tang V; Leung R; Wong H; Chu KW; Poon J; Epstein RJ; Yau T
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6585-90. PubMed ID: 24377572
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer.
Yaman E; Uner A; Er O; Coskun U; Buyukberber S; Dikilitas M; Polat M; Yamac D; Kaya AO; Yildiz R; Ozturk B; Benekli M
Med Oncol; 2007; 24(4):431-5. PubMed ID: 17917094
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
Twelves CJ; Butts CA; Cassidy J; Conroy T; Braud Fd; Diaz-Rubio E; Tabernero JM; Schoffski P; Figer A; Brunet R; Grossmann J; Sobrero AF; Van Cutsem EJ
Clin Colorectal Cancer; 2005 Jul; 5(2):101-7. PubMed ID: 16098250
[TBL] [Abstract][Full Text] [Related]
13. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
[TBL] [Abstract][Full Text] [Related]
14. Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool.
Lin JK; Tan EC; Yang MC
Health Qual Life Outcomes; 2015 May; 13():61. PubMed ID: 25986478
[TBL] [Abstract][Full Text] [Related]
15. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
[TBL] [Abstract][Full Text] [Related]
16. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.
Li YH; Luo HY; Wang FH; Wang ZQ; Qiu MZ; Shi YX; Xiang XJ; Chen XQ; He YJ; Xu RH
J Cancer Res Clin Oncol; 2010 Apr; 136(4):503-10. PubMed ID: 19777259
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D
Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG
J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]